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Purpose of the study
Once-daily (QD) atazanavir/ritonavir (ATV/r) + 2NRTIs
has proven efficacy with favourable lipid and GI profiles
in treatment-experienced and -naive HIV patients (pts).
Data are needed on effective simplified treatment strate-
gies.
Methods
AI424136 (INDUMA) is a randomised, open-label, mult-
icentre study to assess non-inferiority (15% margin) of
48-week maintenance phase (MP) with ATV 400 mg QD
vs. ATV/r 300/100 mg QD (1:1), both + 2NRTIs (excl.
TDF), in patients with confirmed HIV-1 RNA <50 c/mL-
after a 26–30 week induction phase (IP) with ATV/r +
2NRTIs in treatment-naive pts. Primary end-point was
proportion of pts with HIV-RNA <50 c/mL through week
48 of MP. Secondary end-points included, percent with
HIV RNA <400 c/mL, CD4 cell count change, and safety of
MP.
Summary of results
252 pts entered IP (median CD4 245 cells/mm3; median
HIV-RNA 4.95 log10 c/mL), during which 30 pts discon-
tinued (nine for AEs). At the end of IP (EoI), 50 were not
suppressed and were continued on ATV/r regimen (not
described here), and 172 were randomised to MP. Demo-
graphics and EoI subject characteristics for MP were well-
balanced: median CD4 390 cells/mm3; half of pts were on
3TC+ABC. Through week 48 of MP the ATV arm demon-
strated similar (non-inferior) efficacy compared to the
ATV/r arm. (Table 1.)
During MP, mean change in CD4 cell count at week 48
was +92 (SE = 18.1) cells/mm3 for ATV/r and +100 (SE =
14.7) cells/mm3 for ATV; discontinuations prior to week
48 were: ATV/r 14%; ATV 8%. Seven pts on ATV/r and 11
on ATV experienced virological rebound, none had emer-
gence of PI resistance. AEs led to discontinuation in 5%
and 1% of pts on ATV/r & ATV, respectively. Lab grade 3–4
total bilirubin was reported in 47% and 14% on ATV/r &
ATV, respectively. Mean percent triglyceride change from
EoI to week 48 of MP was +9.8 vs. -27.0 for ATV/r & ATV,
respectively. The percent of pts who shifted into higher
NCEP categories from EoI to week 48 of MP was higher in
ATV/r than ATV for total cholesterol (23 vs. 10) and trig-
lycerides (20 vs. 3).
Conclusion
These results are consistent with the proven efficacy of ata-
zanavir in naive pts and suggest that for those pts who
have achieved undetectability under ATV/r, switching to
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unboosted ATV may be an option that results in simplifi-
cation of treatment regimen.
Table 1: 
Proportion of pts with HIV RNA <50/400 c/mL 
through Wk 48 of MP (ITT)
ATV/r (N = 85) ATV (N = 87) Difference Estimate (95%CI) (ATV – ATV/r)
% <50 c/mL 75 78 2.9 (69.8, 15.5)
% <400 c/mL 81 86Page 2 of 2
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